Abstracts tagged "Systemic sclerosis"

Abstract Number: 1857 • ACR Convergence 2021
Ultra-High Frequency Ultrasound Compared to Durometry and Skin Score for Cutaneous Assessment in Systemic Sclerosis
Marco Di Battista¹, Saverio Vitali², Simone Barsotti³, Alessandra Della Rossa⁴, Valentina Dini⁵, Marco Romanelli⁵ and Marta Mosca³, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Radiology Unit - University of Pisa, Pisa, Italy, ³Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁴Rheumatology Unit - University of Pisa, Pisa, Italy, ⁵Dermatology Unit - University of Pisa, Pisa, Italy
Background/Purpose: To assess skin involvement in a cohort of patients with systemic sclerosis (SSc) comparing results obtained from modified Rodnan skin score (mRSS), durometry and…
Abstract Number: 0402 • ACR Convergence 2021
What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?
Alain Lescoat¹, Susan Murphy², Yen Chen³, Nadia Vann¹, David Cella⁴ and Dinesh Khanna³, ¹Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Michigan, Grosse Ile, MI, ³University of Michigan, Ann Arbor, MI, ⁴Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…
Abstract Number: 0549 • ACR Convergence 2021
Upregulation of Prostanoid EP2 Receptors and Meditation of Treprostinil Anti-Proliferative Effects in Scleroderma Smooth Muscle Cells
Yongqing Wang¹, Nezam Altorok² and Bashar Kahaleh², ¹University of Toledo Medical Center, Toledo, OH, ²University of Toledo, Toledo, OH
Background/Purpose: Progressive functional and structural vascular disorder is one of the hallmark features of Systemic Sclerosis (Scleroderma, SSc). Vascular dysfunction leads to dysregulated vascular tone…
Abstract Number: 1044 • ACR Convergence 2021
Older Patients with Rheumatic Disease Are Commonly Prescribed Potentially Inappropriate Medications
Christine Anastasiou, Michael Evans, Gabriela Schmajuk and Jinoos Yazdany, University of California San Francisco, San Francisco, CA
Background/Purpose: Reducing exposure to potentially inappropriate medications (PIMs) in older adults may minimize adverse drug events. The American Geriatrics Society (AGS) Beers Criteria® of Potentially…
Abstract Number: 1378 • ACR Convergence 2021
Presence of Anti-RNA Polymerase 3 Antibody in Systemic Sclerosis, Renal Disease, Malignancy and ILD from a Single Academic Center Cohort
Matthew Kirkpatrick¹, Janet Lee¹, Anne Tebo², Haojia Li¹, yue zhang¹ and Tracy Frech¹, ¹University of Utah, Salt Lake City, UT, ²Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Autoantibodies are included in the disease classification criteria for systemic sclerosis (SSc). Our group previously reported the level of topoisomerase autoantibody as an important…
Abstract Number: 1839 • ACR Convergence 2021
Hispanic Patients with Systemic Sclerosis Have More Severe Disease and Higher Mortality: A Longitudinal Cohort Study
Bochra Jandali¹, Marka Lyons², Julio Charles², Maureen Mayes³ and Shervin Assassi¹, ¹University of Texas McGovern Medical School at Houston, Houston, TX, ²Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX, ³Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Systemic sclerosis (SSc) shows disparities in incidence, disease manifestations, and prognosis in different ethnic groups. The data regarding disease characteristics and outcomes in Hispanic…
Abstract Number: 1860 • ACR Convergence 2021
Three Distinct Transcriptional Profiles of Monocytes Correlate with Disease Activity in SSc Patients
Hadijat Makinde¹, Gaurav Gadhvi¹, Salina Dominguez¹, Miranda Gurra¹, Kathleen Aren², Mary Carns², Tracy Frech³, Dinesh Khanna⁴, Shervin Assassi⁵, Lutfiyya Muhammad⁶, Carla Cuda¹, Monique Hinchcliff⁷, Deborah Winter² and Harris Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University Division of Rheumatology, Chicago, IL, ³University of Utah, Salt Lake City, UT, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Texas McGovern Medical School at Houston, Houston, TX, ⁶Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Yale School of Medicine, Westport, CT
Background/Purpose: Patients with SSc display a complex clinical phenotype.Our group has made important contributions to an emerging understanding of monocytes and macrophages as central to…
Abstract Number: 0403 • ACR Convergence 2021
Effect of Nintedanib on KL-6 in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
Shervin Assassi¹, Christopher Denton², Maurizio Cutolo³, Tracy Luckhardt⁴, Claudia Diefenbach⁵, Carina Ittrich⁶, Margarida Alves⁷ and Masataka Kuwana⁸, ¹University of Texas McGovern Medical School at Houston, Houston, TX, ²University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ³Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ⁴University of Alabama, Birmingham, AL, ⁵Boehringer Ingelheim Pharma GmBH, Biberach an der Riss, Germany, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁸Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Krebs von den Lungen-6 (KL-6), a marker of lung epithelial and endothelial injury, has been associated with progression of interstitial lung disease associated with…
Abstract Number: 0550 • ACR Convergence 2021
Treatment Regimens and Outcomes in Systemic Sclerosis-associated Pulmonary Arterial Hypertension
Hilde Jenssen Bjørkekjær¹, Håvard Fretheim², Helene Marjavara Inselseth³, Øyvind Midtvedt⁴, Imon Barua⁴, Torhild Garen⁵, Helle Bitter¹, Arne Andreassen⁶, Øyvind Molberg⁴, Kaspar Broch⁶ and Anna-Maria Hoffmann-Vold⁴, ¹Department of Rheumatology, Sørlandet sykehus HF, Kristiansand, Norway, ²Oslo University Hospital, Oslo, Norway, ³University of Oslo, Oslo, Norway, ⁴Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁵Department of Rheumatology, Oslo University Hospital, Oslo, Nepal, ⁶Department of Cardiology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc). It is associated with impaired quality of life and high mortality.…
Abstract Number: 1047 • ACR Convergence 2021
Exposure to Industrial Pollutants and Mortality Due to Inmune-mediated Inflammatory Systemic Diseases (IMD) in Spain
ana Perez¹, Arturo Rodriguez Pérez², Pablo Fernandez-Navarro³, Fernando Albarran⁴, Cristina Bohorquez⁴, Atusa Movasat⁴, Lucia Ruiz⁴, Paula Pretel⁴, elena Rabadan⁴, Valentina Emperiale⁴, Adrian abbasi⁵, julio suarez⁵, Lorena Montano⁴, emilio rico⁵, alfredo prieto², melchor Alvarez de Mon⁵ and beatriz perez³, ¹Hospital Universitario Príncipe de Asturias. Rheumatology. Medicine Faculty. Alcala University Department., Madrid, Spain, ²Faculty of Medicine. Alcala University, Alcala de Henares, Spain, ³Department of Epidemiology of Chronic Diseases.National Center of Epidemiology/CIBERESP. Instituto de Salud Carlos III, Madrid, Spain, ⁴Hospital Universitario Príncipe de Asturias, Rheumatology Department, Alcala de Henares, ⁵Hospital Universitario Príncipe de Asturias, Madrid, Spain
Background/Purpose: The etiology of many IMD is largely unknown; however, available data suggest that environmental contaminants could play a role in their origin. Industrial facilities…
Abstract Number: 1382 • ACR Convergence 2021
Survey on Treatment Practices in Subclinical Interstitial Lung Disease in Systemic Sclerosis
Sabrina Hoa¹, Murray Baron² and Marie Hudson³, ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Jewish General Hospital, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in systemic sclerosis (SSc). Early detection and treatment of SSc-ILD may lead to improved…
Abstract Number: 1840 • ACR Convergence 2021
Can Dual-energy CT Lung Perfusion Detect Abnormalities at the Level of Lung Circulation in Systemic Sclerosis (SSc) ? Preliminary Experience in 101 Patients
Vincent Koether¹, Antoine Dupont², Julien Labreuche³, Paul Felloni⁴, Thierry Perez⁵, Pascal Degroote⁵, Jacques Remy⁴, Martine Remy-Jardin⁵ and David Launay⁶, ¹CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de référence des maladies autoimmunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ²CHRU de Lille, Hopital Calmette, Lille, France, ³CHU Lille, Lille, ⁴CHU Lille; Hopital Calmette, Lille, France, ⁵CHU Lille, Lille, France, ⁶Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France, Lille Cedex, France
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disorder that is characterized by a interplay of vascular abnormalities, immune system activation and an uncontrolled fibrotic response…
Abstract Number: 1861 • ACR Convergence 2021
Epidermal Growth Factor Receptor Pathway and Fibrosis in Systemic Sclerosis Skin
Miruna Carnaru¹, Monique Hinchcliff², Ian Odell¹ and F. Perry Wilson³, ¹Yale School Of Medicine, New Haven, CT, ²Yale School of Medicine, Westport, CT, ³Section of Nephrology, Department of Medicine, Yale School of Medicine, New Haven, CT; Department of Medicine Clinical and Translational Research Accelerator Yale School of Medicine, New Haven, CT
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disorder with chronic morbidity and high mortality. Disease pathogenesis involves microvascular damage, immune dysregulation, and fibrosis affecting…
Abstract Number: 0404 • ACR Convergence 2021
Perifollicular Hypopigmentation in Systemic Sclerosis: Associations with Clinical Features and Internal Organ Involvement
Melody Chung¹, Jamie Perin¹, Carrie Richardson², Christopher Mecoli³, Fred Wigley¹ and Zsuzsanna McMahan⁴, ¹Johns Hopkins University, Baltimore, MD, ²Rush University Medical Center, Chicago, IL, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Among the autoimmune rheumatic diseases, there is precedent for utilizing cutaneous manifestations of systemic disease as clues to clinical phenotype and disease prognosis. Though…
Abstract Number: 0551 • ACR Convergence 2021
Metabolic Intermediate Dimethyl-Alpha-Ketoglutarate Is a Novel Repressor of Pathogenic Myofibroblast Reprogramming and Skin Fibrosis in Systemic Sclerosis
Blaž Burja¹, Ishani Banik², Shervin Assassi³, Michael Whitfield⁴, J. Matthew Mahoney⁵, Andreja Erman⁶, Matija Tomšič⁷, Mitchell P. Levesque², Snežna Sodin-Šemrl⁷, Gabriela Kania⁸, Hubert Rehrauer⁹, Ziga Rotar⁷, Oliver Distler¹⁰, Katja Lakota¹¹ and Mojca Frank-Bertoncelj¹⁰, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich and Department of Rheumatology, University Medical Centre Ljubljana, Zurich, Switzerland, ²Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³University of Texas McGovern Medical School at Houston, Houston, TX, ⁴Geisel School of Medicine, Lebanon, NH, ⁵Center for Quantitative Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁶Institute for Cell Biology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁷Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁸Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁹Functional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich, Switzerland, ¹⁰Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ¹¹Department of Rheumatology, University Medical Centre Ljubljana, Llubljana, Slovenia
Background/Purpose: Metabolic perturbations drive fibroblast-to-myofibroblast reprogramming and tissue fibrosis. Restoring perturbed metabolism might represent a new antifibrotic strategy. Here we explored the capacity of dimethyl-alpha-ketoglutarate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].